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INTRODUCTION
Multidrug-resistant tuberculosis (MDR-TB), defined as a
disease caused by strains of Mycobacterium tuberculosis that are
resistant to at least isoniazid and rifampin, is recognized as
an important global threat (1). Current therapy for MDR-TB
is the combination of second-line antituberculous drugs, and
resectional surgery can be sometimes combined with antitu-
berculous chemotherapy (2, 3). Until now, however, there has
been no definite treatment modality in the patients with refrac-
tory MDR-TB, who have persistent positive sputum culture
for M. tuberculosis despite prolonged antituberculous chemother-
apy and who are not candidates for resectional surgery due to
extensive bilateral disease.
Interferon-gamma (IFN- ) has been shown to activate mono-
cytes and macrophages against M. tuberculosis in vitro (4-6).
Some clinical efficacy has also been shown for IFN- given
systemically to treat disseminated M. avium complex infections
in immunocompromised hosts without infection of human
immunodeficiency virus (HIV) or patients with AIDS (7, 8).
In addition, Condos et al. reported transient but clinically
encouraging improvements in five patients with MDR-TB
following one month of IFN- inhalation therapy. Respon-
ses included the conversion of sputum smears to negative, de-
layed growth of cultures, and shrinkage of cavities (9).
However, there have been no further reports about long-
term effects of IFN- inhalation therapy in the treatment of
MDR-TB. Therefore, we studied the effects of IFN- inhala-
tion therapy for six months in the treatment of refractory
MDR-TB.
MATERIALS AND METHODS
Six patients with sputum-smear-positive and culture-pos-
itive cavitary MDR-TB that was refractory to antituberculous
chemotherapy were evaluated in an open-labeled, nonrandom-
ized observational study. The study was approved by the insti-
tutional review boards, and informed consent was obtained
from all patients.
All patients were chronic cases according to the case defi-
nition criteria of World Health Organization (10) and had a
refractory MDR-TB and radiological progression of disease
despite adequate chemotherapy for at least six months based
on the past drug history and individual susceptibility test re-
sults. No patient was indicated for resectional surgery because
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Six-month Therapy with Aerosolized Interferon-γfor Refractory
Multidrug-Resistant Pulmonary Tuberculosis
The aim of this study was to investigate the adjuvant effects of interferon-gamma
(IFN- ) inhalation therapy for six months in the treatment of refractory multidrug-resis-
tant pulmonary tuberculosis (MDR-TB). Aerosolized IFN- was given to six MDR-
TB patients with persistent positive smears and cultures despite long-term medical
treatment. The patients received aerosolized two million international units of IFN-
three times a week for 6 months while they continued on identical antituberculous
chemotherapy. Before IFN- inhalation therapy, the patients received a median of
6.5 (range, 4 to 7) antituberculous drugs for median duration of 29 months (range,
7 to 76). After IFN- inhalation therapy, sputum smears remained persistently pos-
itive in all patients throughout the study period. Sputum cultures were transiently
negative at the 4th month in two patients, but became positive again at the end of
6 months of IFN- therapy. Five patients had radiological improvement including
three patients who showed a decrease in the size of the cavitary lesions. Resec-
tional surgery could be performed in one patient in whom substantial clinical and
radiological improvement was noted after IFN- inhalation therapy. These results
suggest that IFN- inhalation therapy may be effective for some cases of refractory
MDR-TB who are otherwise not responding to conventional therapy.
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of extensive bilateral disease including cavitary lesions. No
patient was infected by HIV. IFN- inhalation therapy was
added to chemotherapeutic regimens only if there was no im-
provement in the patient’ s clinical, microbiological, and radi-
ological conditions. 
Recombinant human IFN- (LGCI Ltd. Seoul, Republic of
Korea) in a dose of two million international units was given
via nebulizer three times weekly for six months. All patients
continued to receive the same antituberculous medications
that they had received previously. Treatment was given on an
outpatient basis. Treatment and surveillance for adverse events
were monitored and managed by the attending physician.
Monitoring of renal and hepatic function was performed reg-
ularly during therapy. Sputum examinations and posterior-
anterior chest radiographies were done bimonthly. One patient
had a computed tomography scan of the chest at baseline and
on completion of the IFN- inhalation therapy on the basis
of the judgment of the treating clinician. Posterior-anterior
chest radiographies and computed tomography scans exam-
ined at the baseline and after completion of treatment were
reviewed by two experienced chest radiologists.
RESULTS
The patient’ s characteristics are shown in Table 1. There
were three men and three women. The median duration of
disease before IFN- inhalation therapy was 29 months (range,
7 to 76). The median number of drugs used previously was
6.5 (range, 4 to 7).
All patients tolerated the therapy well. Routine laboratory
assessments done throughout the study showed no abnormal-
ities.
All patients were sputum-smear and sputum-culture pos-
itive despite prolonged chemotherapy. For the 6-month peri-
od of IFN- inhalation therapy, no patient had become spu-
tum-smear negative. Also sputum cultures remained positive
for all patients at the end of the IFN- inhalation therapy. In
Patients 3 and 5, the sputum cultures were negative at the
4th month, but became positive again at the end of 6 months
of IFN- inhalation therapy (Table 2).
Chest radiographs done at the baseline were compared with
those taken after 6 months of IFN- inhalation therapy. Five
patients had improvement of infiltration and three patients
showed decrease in the size of the cavitary lesions (Table 2).
One patient (Patient 5) who was not initially considered as
a candidate for surgery successfully received pulmonary resec-
tional surgery after 6 months of IFN- inhalation therapy com-
bined with chemotherapy due to substantial clinical and radi-
ological improvements.
This 27-yr-old immunocompetent male was presented to
our hospital with a 6-yr history of refractory pulmonary tuber-
Patient No.*
Sex/Age
(yr)
No. of drugs to which isolate was 
resistant in vitro (first-line drugs)
Current drug regimen
� Treatment of duration on current regimen
before interferon- therapy (mo)
1 F/34 5 (4) PTH, CS, PAS, LFX, AMXC, CLA, KM 7
2 F/55 5 (3) EMB, PTH, CS, PAS, LFX, KM 34
3 F/61 8 (5) INH, CS, LFX, VM 76
4 M/60 5 (4) PZA, PTH, CS, PAS, OFX, AMXC, KM 24
5 M/27 8 (5) PTH, CS, PAS, LFX, AMXC, CLA 48
6 M/36 5 (4) EMB, PZA, PTH, CS, OFX, AMXC, KM 16
*The patients are numbered according to the order of entry. 
� PTH, prothionamide; CS, cycloserine; PAS, para-aminosalicylic acid; LFX, levofloxacin;
AMXC, amoxicillin-clavulanic acid; CLA, clarithromycin; KM, kanamycin; EMB, ethambutol; INH, isoniazid; EVM, enviomycin; PZA, pyrazinamide;
OFX, ofloxacin.
Table 1. Characteristics of the six patients with multidrug-resistant tuberculosis treated with interferon-gamma
Patient No.
Sex/Age
(yr)
Sputum Smear*/Culture
�
Before interferon-
therapy
After starting of interferon- therapy Improvement of
infiltration
Decrease in
size of cavity
Chest Radiograph
after interferon-gamma therapy
2 mo 4 mo 6 mo
1 F/34 4+/2+ 4+/1+ 4+/3+ 4+/2+ Yes No
2 F/55 4+/2+ 3+/± 4+/2+ 4+/1+ No No
3 F/61 4+/1+ 4+/3+ 3+/- 4+/3+ Yes Yes
4 M/60 2+/3+ 3+/2+ 1+/3+ 2+/1+ Yes No
5 M/27 2+/1+ 3+/1+ 1+/- 3+/± Yes Yes
6 M/36 3+/3+ 2+/2+ 1+/2+ 1+/± Yes Yes
*Sputum smear: ±, 1-2 organisms/300 fields; 1+, 1-9 organisms/100 fields; 2+, 1-9 organisms/10 fields; 3+, 1-9 organisms/1 field; 4+, >9 organisms/1
field (10). 
� Sputum culture: -, no colonies seen; ±, <50 colonies; 1+, 100-200 colonies; 3+, 200-500 colonies (almost confluence); 4+, >500 colonies
(confluence) (10).
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culosis. Pulmonary tuberculosis had been diagnosed 6 yr ago,
at which time he was treated with isoniazid, rifampin, etham-
butol, and pyrazinamide. Results of drug susceptibility test
showed that isolated M. tuberculosis was resistant to isoniazid
and rifampin and had been on various second-line antituber-
culous drugs since then. The sputum cultures, however, had
remained persistently positive for M. tuberculosis despite a 5-
yr history of medical treatment.
Upon presentation to our hospital, sputum examination
showed smear and culture positivity and his chest radiography
revealed a large cavity in the right upper lobe and progressive
infiltrations in the left upper lobe and both lower lobes (Fig.
1A). Recent drug susceptibility test revealed extensive resis-
tance to isoniazid, rifampin, ethambutol, pyrazinamide, strep-
tomycin, and ofloxacin. Prothionamide, cycloserine, para-ami-
nosalicylic acid, levofloxacin, amoxicillin-clavulonic acid, and
clarithromycin were prescribed. Six months later, he became
clinically worse, with cough, sputum, and anorexia. Sputum
smears for acid-fast bacilli were positive, and cultures yielded
growth of M. tuberculosis. The extent of radiographic infiltra-
tions, especially on the left side, had increased (Fig. 1B). At
that time, resectional surgery could not be considered due to
progressive bilateral lesions.
The patient received IFN- inhalation therapy combined
with previously prescribed chemotherapy. Six months later
there was a decrease of cavity size in the right upper lobe and,
more importantly, improvement of nodular infiltrates in the
left upper lobe and both lower lobes (Fig. 1C). Resectional
Fig. 1. 27-yr-old male patient with multidrug-resistant tuberculosis.
(A) Computed tomographic scan of the chest showed multiple cavi-
ties in the right upper lobe and small nodular infiltrations in the left
upper lobe. (B) The extent of radiographic infiltrations of the left upper
lobe increased despite 6 months of antituberculous chemotherapy.
(C) After 6 months of IFN- inhalation therapy, computed tomogr-
aphic scan showed reduction in the size of cavitary lesions in the
right upper lobe and improvement of nodular infiltrates in the left
upper lobe.
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surgery was considered because of previous failure of medical
treatment alone. Right upper lobectomy and wedge resection
of the right lower lobe were successfully performed without
perioperative complications. Negative conversion of sputum
smear and culture was established postoperatively.
DISCUSSION
MDR-TB is a serious life-threatening condition that is
associated with a high degree of morbidity and mortality. In
1993, the National Jewish Center for Immunology and Res-
piratory Medicine reported 22% mortality attributable to
MDR-TB and only 56% of MDR-TB patients were disease
free after a mean follow-up period of 51 months (12).
Recently, the development of modern immunology has led
to new investigational therapeutic approach, that is cytokine
therapy, in the treatment of MDR-TB. One of the targeted
cytokines is IFN- (9, 13, 14). There is a scientific rationale
for the use of IFN- in MDR-TB. By activating macrophages
and promoting a range of host immune responses, IFN- may
provide an effective adjunct to antituberculous agents in pa-
tients who are not responding to conventional courses of ther-
apy. IFN- enhances antigen processing and presentation to
lymphocytes through the induction of major histocompati-
bility complex class II antigens. It also acts on T lymphocytes,
stimulating a differentiation toward a Th1-type of immune
response (6, 9, 13, 14).
IFN- has been used for the prophylactic treatment of chron-
ic granulomatous disease and long-term follow-up of these
patients who have received up to 10 yr of IFN- has shown
no unexpected toxicity (15). These data indicated that long-
term IFN- therapy appears safe and well tolerated in humans.
IFN- has been used successfully as an adjuvant in the treat-
ment of human mycobacterial infections; leprosy, nontuber-
culous mycobacterial infection, and tuberculosis (7-9, 13, 16).
However, clinical experience with IFN- for the treatment of
pulmonary tuberculosis is still limited. Raad et al. described
a patient with acute lymphocytic leukemia in remission who
had MDR-TB involving the brain and spinal cord that was
steroid-dependent. Subcutaneous IFN- therapy allowed rapid
reduction in steroid dose and led to cure without any exacer-
bation of central nervous system inflammation (13). Condos
et al. used IFN- aerosol for four weeks in five patients with
long-standing MDR-TB refractory to medical treatment (9).
Sputum acid-fast-bacillus smears became negative and the
size of cavitary lesions was reduced in all patients suggesting
that IFN- might be useful as an adjunctive therapy in patients
with MDR-TB. With this short course of therapy, culture
conversion did not occur and all patients again had positive
smears after cessation of IFN- . However, no patient worsened
during therapy, and there were no significant systemic or local
complaints. These data suggested that IFN- inhalation ther-
apy could be well tolerated and useful in some patients with
MDR-TB.
The six patients described here had persistent MDR-TB
that was refractory to appropriate therapy with conventional
antituberculous agents. After the six-month therapy, sputum
smears of our patients were persistently positive for the entire
six months and sputum cultures were positive at the end of
the period in all patients in spite of transient negative con-
version in two patients. These results were not consistent with
the results of Condos et al. which showed transient clearing
of smears in all patients. The difference between our experi-
ence and that of Condos et al. may be related to the aerosol
dose of IFN- that our patients received; our patients were
taking two million international units of IFN- which were
equivalent to 100  g and Condos et al. used 500  g of IFN- .
In particular, all patients except one patient showed radi-
ological responses. The most obvious responses were improve-
ments of infiltration such as nodules, reticulonodular opacities,
which were noticed in five (83%) patients. However, reduc-
tion in the size of cavitary lesions was observed in only three
(50%) patients.
Interestingly, one patient showed substantial clinical and
radiological improvement and then resectional surgery could
be performed. To our knowledge, this is the first reported case
of refractory MDR-TB in the lung, which was successfully
treated with adjunctive IFN- inhalation therapy combined
with surgical management and antituberculous drugs. This
result suggested that IFN- inhalation therapy may play a
role of the bridge to pulmonary resection in selected patients
who have initially equivocal indication of resectional surgery
due to bilateral active disease. These findings suggested that
IFN- inhalation therapy may be a powerful adjunct to con-
ventional therapy, especially in the patients with less destruc-
tive parenchymal lesion such as nodular infiltration without
cavitary lesions which have a large burden of mycobacterium.
The current study is limited by the small sample size, but
the results suggest that IFN- inhalation therapy might be an
acceptable adjunctive therapy. The distinctive role of IFN-
in the adjunctive treatment of MDR-TB should be further
investigated to determine the criteria of potential candidates
and optimal duration of therapy.
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